Pharmaceutical News

RSS

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

The natural-occurring biopolymer known as chitosan is being put forward as an effective alternative to growth-promoting antibiotics in the diet of ruminants, according to research carried out by scientists at the Basque technological centre, Neiker-Tecnalia.

1 Mar 2010

Pharmacist workforce: Work characteristics and contributions

Results released today from the Pharmacy Manpower Project’s 2009 National Pharmacist Workforce Survey indicate shifts in the pharmacy profession toward more patient care. This 2009 report also provides insight into how the nation’s current economic situation has influenced the dynamics of the U.S. pharmacy workforce as nearly a quarter of pharmacists are practicing part-time and more are working past retirement age. This study is the third in a series of surveys commissioned by the Pharmacy Manpower Project, Inc. (PMP) since 2000 and has been highly anticipated throughout the industry.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.

1 Mar 2010

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.

1 Mar 2010

Blacks less likely to know they have atrial fibrillation or about use of warfarin

A large nationwide study that includes neurologists from Mayo Clinic has found that blacks are substantially less likely than whites to know that they have atrial fibrillation or to use warfarin, the most common treatment for the condition. Atrial fibrillation, an abnormal heart rhythm, significantly increases risk of stroke. Warfarin is known to reduce that risk.

27 Feb 2010

Single submission of orphan drug designation annual report for both FDA and EMA

In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.

27 Feb 2010

Canada's pharmaceutical products industry stands out strong during recession

Canada's pharmaceutical products industry stands out for its strong growth during the 2008-09 recession. This sets it apart from other industries covered in the Winter 2010 edition of The Conference Board of Canada's Canadian Industrial Profile Service - chemicals, plastic and rubber products, non-metallic mineral products, and computer and electronic products, which will take at least a couple of years to return to pre-recession production, revenue and profit levels.

27 Feb 2010

Midlothian Laboratories donates more than $3M worth of vitamins, nutritional supplements to AmeriCares

Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

26 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

26 Feb 2010

Pharmaceutical News

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

Pharmacist workforce: Work characteristics and contributions

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

Blacks less likely to know they have atrial fibrillation or about use of warfarin

Single submission of orphan drug designation annual report for both FDA and EMA

Canada's pharmaceutical products industry stands out strong during recession

Midlothian Laboratories donates more than $3M worth of vitamins, nutritional supplements to AmeriCares

Shire receives marketing approval from FDA for VPRIV

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

Gaucher disease: FDA approves VPRIV

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News